Rise in patient reporting boosts EU drug safety signals
This article was originally published in Scrip
Executive Summary
The introduction of direct reporting of adverse drug reactions by patients in Europe appears to have had the desired effect: in 2013, the number of ADRs reported by patients within the European Economic Area (EEA) rose by more than 50% as a result of greater public awareness of the importance of such reporting.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.